

Greffex, Inc. Awarded NIH Contract for up to \$18.9 Million to Develop a Plug-And-Play Technology Platform to Expedite the Production of Vaccine Candidates for Biodefense and Emerging Infectious Diseases.

NEWS PROVIDED BY: Greffex, Inc. September 9, 2019

HOUSTON, TX., September 9, 2019 -- GREFFEX, INC. won a contract of up to \$18.9 million with the National Institute of Health's National Institute for Allergy and Infectious Diseases to develop and exploit its GreVac(TM) *Plug-And-Play Technology to Expedite the Production of Vaccine Candidates for Biodefense and Emerging Infectious Diseases* to target emerging infectious threats, whether natural or man-made.

GreVac(TM) vaccines are based upon GREFFEX's proprietary GreGT Genetic Engineering Technology as a fast and flexible plug-and-play vaccine architecture of fully deleted helper virus-independent adenoviral vectors of rare serotypes. The proprietary GreGT platform has been built upon two independently modifiable components to provide broad gene transfer applications.

The GreVac(TM) system incorporates versatility and speed to complement and ultimately change the present paradigm of

immune protection against infectious diseases with a high eruption potential from the stockpiling of potential vaccine candidates to the *just-in-time* production of specific vaccines.

With support by the present NIH contract, GREFFEX expects to advance the development of two of its GreVac(TM) influenza vaccines through clinical trials. The activity of a vaccine directed against a highly pathogenic avian influenza will be compared to a novel universal influenza vaccine. This research initiative is funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract HHS-NIH-NIAID-BAA2018 (BAA-2018 Omnibus Broad Agency Announcement: Research Area 2 (DMID) - Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases).

About Greffex

Founded in 2005 to pursue disruptive and proprietary technology that its founders had first explored in 1998, GREFFEX has created the most versatile gene delivery vehicle with broad applications in vaccination, gene therapy and tissue engineering and, in process, has become a leading Genetic Engineering Company. The company has 14 vaccines in its development portfolio, numerous gene therapies in development including Hemophilia A and Usher Syndrome, and immune tissue engineering aimed at overcoming transplant rejection. GREFFEX is headquartered in Houston, Texas and its laboratories are located in Aurora, Colorado. Direct all questions regarding this release to: cgray@greffex.com

Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the position or policy of the Government and no official endorsement should be inferred.

